Skip to content

Atazanavir, once daily protease inhibitor, now available in UK

Risk factors for non improvement in HAART adherence identified in MACS

Surgical options provide good long-term improvement in buffalo hump

NRTI toxicity may be associated with increased cellular activation due to advanced disease

Life-threatening allergic reaction after a single dose of abacavir reported

UK to give £3 million to WHO 3 x 5 programme

Differences found between patients stopping HAART for medical or lifestyle reasons

UN AIDS envoy raises alarm over funding for 3 x 5; 98% shortfall for 2004

Once-daily combined abacavir/3TC pill available in the UK on a named patient basis